Lee Ainslie Viridian Therapeutics, Inc.\De Transaction History
Maverick Capital LTD
- $5.07 Billion
- Q2 2024
A detailed history of Lee Ainslie (Maverick Capital LTD) transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Maverick Capital LTD holds 3,307,945 shares of VRDN stock, worth $81.7 Million. This represents 0.85% of its overall portfolio holdings.
Number of Shares
3,307,945
Previous 2,692,414
22.86%
Holding current value
$81.7 Million
Previous $47.1 Million
8.71%
% of portfolio
0.85%
Previous 0.94%
Shares
3 transactions
Others Institutions Holding VRDN
# of Institutions
153Shares Held
62.2MCall Options Held
133KPut Options Held
207K-
Black Rock Inc. New York, NY4.77MShares$118 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.92MShares$97 Million1.68% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$95.9 Million5.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.35MShares$82.7 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.9MShares$71.6 Million1.52% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $986M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...